PRKCD and Alzheimer disease: For example, increased PKCδ levels are observed in the brain of AD patients and may contribute to heightened expression of the beta-site APP cleaving enzyme-1 (BACE1), and, consistently, knockdown of PKCδ reduces Aβ production in APPswe/PS1dE9 transgenic mice [10].